Coronary artery disease in women: A review of emerging cardiovascular risk factors

Mount Sinai Journal of Medicine

Volumn 69, Issue 5, 2002, Pages 338-349

  Nguyen, Van Hong D ^a   McLaughlin, Mary Ann ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Coronary heart disease; Pathophysiology; Women

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID A PROTEIN; ANTILIPEMIC AGENT; ANTIOXIDANT; C REACTIVE PROTEIN; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRINOGEN; FOLIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPROTEIN A; NICOTINIC ACID; PYRIDOXINE; RAMIPRIL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM INJURY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPOCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID STORAGE; MORTALITY; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; RISK FACTOR; SEX DIFFERENCE;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); OXIDATIVE STRESS; RISK FACTORS; THROMBOPHILIA; WOMEN'S HEALTH;

EID: 0036773399     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas (TX): American Heart Association; 2000.
2. Brown KS. Heart disease: Women's unique risks demand attention. Ann Intern Med 1997; 127:952-953.
3. Barrett-Connor E. Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: A prospective population-based study. Am J Epidemiol 1983; 118:489-496.
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657-671.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844-2850.
7. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995; 76:24C-33C.
8. Morrow DA, Ridker PM. C-reactivc protein, inflammation, and coronary risk. Med Clin North Am 2000; 84:149-161, ix.
9. Ridker PM, Baring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-733.
10. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
11. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction, Circulation 1998; 97:2007-2011.
12. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331:417-424.
13. Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999; 100:1958-1963.
14. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98:839-844.
15. Ridker PM, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med 1998; 46:391-395.
16. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999: 100:717-722.
17. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100:713-716.
18. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
19. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343;522-529.
20. Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand Suppl 1938; 89:45-84.
21. Castelli W, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256:2835-2838.
22. Kwiterovich PO. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82:13Q-21Q.
23. Gordon DJ, Knoke J, Probstfield JL, et al. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986; 74:1217-1225.
24. Frick MH, Manninen V, Huttunen JK, et al. HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study. Drugs 1990; 40:7-12.
25. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
26. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 1992; 2:161-176.
27. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274:539-544.
28. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86:379-384.
29. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992; 70:3H-9H.
30. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32:300-304.
31. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81:7B-12B.
32. Gaziano JM, Hennekens CH, O'Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96:2520-2525.
33. Goldschmid MG, Barrett-Connor E, Edelstein SL, et al. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation 1994; 89:991-997.
34. Miettinen M, Turpeinen O, Karvonen MJ, et al. Effect of cholesterol-lowering diet on mortality from coronary-heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet 1972; 2:835-838.
35. Frantz ID, Jr, Dawson EA, Ashman PL, et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis 1989; 9:129-135.
36. Dorr AE, Gundersen K, Schneider JC, et al. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chronic Dis 1978; 31:5-14.
37. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
38. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
39. Kjeckshus J, Pedersen TR. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76:64C-68C.
40. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279:1643-1650.
41. Hussein O. Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128:11-18.
42. Loscalzo J, Weinfeld M, Floss GM, Scanu AM. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:240-245.
43. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000; 45:391-418.
44. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994; 90:1688-1695.
45. Yamamoto H, Imazu M, Yamabe T, et al. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: Role of lipoprotein (a). Am Heart J 1995; 130:1168-1173.
46. Miyata M, Biro S, Arima S, et al. High serum concentration of lipoprotein (a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996; 132:269-273.
47. Jorgensen B, Simonsen S, Endresen K, et al. Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids. Eur Heart J 1999; 20:1407-1414.
48. Hoff HF, Beck GJ, Skibinski CI, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988; 77:1238-1244.
49. Skinner JS, Farrer M, Albers CJ, et al. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. Heart 1997; 78:131-135.
50. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408-416.
51. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334:1156-1162.
52. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786.
53. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354:447-455.
54. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154-160.
55. Kritchevsky SB, Shimakawa T, Tell GS, et al. Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 92:2142-2150.
56. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3:194-202.
57. Stampfor MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1444-1449.
58. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993: 328:1450-1456.
59. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273:1849-1854.
60. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-1050.
61. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-881.
62. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96:412-417.
63. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281:1817-1821.
64. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057.
65. Nygärd O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236.
66. Genest JJ, Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11:1129-1136.
67. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59:940-948.
68. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158:862-867.
69. Morris MS, Jacques PF, Selhub J, Rosenberg IH. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2000; 152:140-148.
70. Woo KS, Chook P, Lolin YI, et al. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol 1999; 34:2002-2006.
71. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968-977.
72. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986; 111:383-390.
73. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280:1843-1848.
74. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: The Iowa Women's Health Study. Arch Intern Med 2000; 160:2117-2128.
75. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282:2131-2135.
76. Harlan WR, Landis JR, Flegal KM, et al. Secular trends in body mass in the United States, 1960-1980. Am J Epidemiol 1988; 128:1065-1074.
77. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990; 132:612-628.
78. Blair SN, Kampert JB, Kohl HW, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996; 276:205-210.
79. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343:16-22.
80. Manson JE, Hu FB. Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999, 341:650-658.
81. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118:956-963.
82. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96:1102-1108.
83. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279:1477-1482.
84. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332:635-641.
85. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; 2:988-991.
86. Vorster HH. Fibrinogen and women's health. Thromb Res 1999; 95:137-154.
87. Saito I, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133:81-91.
88. Randi ML, Mares M, Fabris F, et al. Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine. Arzneimittelforschung 1991; 41:414-416.
89. Tohgi H, Takahashi H, Kashiwaya M, Watanabe K. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin. Stroke 1994; 25:2017-2121.
90. de Maat MP, Arnold AE, van Buuren S, et al. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost 1996; 76:166-170.
91. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
92. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98;2241-2247.
93. Salomaa V, Stinson V, Kark JD, et al. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 91:284-290.
94. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94:2057-2063.
95. Brussaard HE, Gevers Leuven JA, Frolich M, et al. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997; 40:843-849.
96. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71:420-423.
97. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91:1952-1958.
98. Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997; 96:442-447.
99. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 1992; 85:1888-1893.